ArticleFrontiers in pharmacology2026
Comparative risk of arrhythmias associated with systemic antifungal agents: a disproportionality analysis of the FAERS database.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The real-world cardiac safety profile of systemic antifungal agents has not been thoroughly investigated. Based on the US Food and Drug Administration Adverse Event Reporting System FDA Adverse Event Reporting System database, this study analyzed the arrhythmogenic toxicity of nine systemic antifungal drugs, aiming to provide references for clinical safe medication practices. Research design and methods: Adverse events were described and classified using arrhythmogenic toxicity-related Standardized MedDRA Queries (SMQs) from the MedDRA. To identify the association between systemic antifungal agents and arrhythmogenic toxicity, this study used four algorithms: Reporting odds ratio (ROR), Proportional reporting ratio (PRR), Multi-item gamma-poisson shrinker (MGPS), and Bayesian confidence propagation Neural Network (BCPNN). Results: A total of 42,393 reports were included. The ranking of the number of positive signals across four types of SMQs was as follows: Itraconazole (4), Fluconazole (3), Posaconazole (3), Voriconazole (2), Caspofungin (1), Amphotericin B (1), Flucytosine (0), Isavuconazole (0), Micafungin (0). Itraconazole demonstrated the strongest ROR value of 2.95 in "Cardiac arrhythmia terms, nonspecific". The highest ROR values in "Bradyarrhythmias" were 5.53 for both posaconazole and fluconazole. Fluconazole exhibited higher ROR values than other drugs in both "Tachyarrhythmias" and "Torsade de pointes/QT prolongation", with values of 3.53 and 14.55, respectively. Conclusion: This study employed four disproportionality analysis methods to analyze the association between systemic antifungal agents and arrhythmogenic toxicity signals. Itraconazole, fluconazole, and posaconazole demonstrated stronger arrhythmogenic risks, whereas micafungin, flucytosine, and isavuconazole showed negative signals across all four SMQs. In clinical practice, individual patient risk should be comprehensively assessed to guide personalized drug selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.